GrowGeneration Beats on Q2 Earnings, Hikes '26 Adjusted EBITDA View

GrowGeneration Corp. (GRWG) reported Q2 2026 results: a 3-cent per-share loss, narrower than the Zacks Consensus estimate of a 4-cent loss and versus an 8-cent loss a year earlier. Sales rose 5.5% to $43.2M. Adjusted EBITDA was $0.3M. The company raised full-year adjusted EBITDA guidance to $2–$3M and reaffirmed sales guidance of $162–$168M.

Original reporting
Published Aug 14, 2026, 2:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 15, 2026, 8:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
GrowGeneration Beats on Q2 Earnings, Hikes '26 Adjusted EBITDA View — source image
Decision brief

The 30-second read

$GRWGBullishMed
01

Why it matters

The key tradable change is the raised full-year adjusted EBITDA outlook to $2-$3 million, supported by improved gross margin mix and lower operating expenses, alongside a sequential sales outlook for Q3.

02

Market read

This is a company-specific earnings and guidance update with enough quantified operating metrics to drive repricing, especially around the shift from breakeven to positive adjusted EBITDA.

03

What to watch

The article cites tariff-related benefits but does not quantify them; traders may discount guidance if tariff timing or magnitude is uncertain.

Relevance 8/10Novelty 7/10Timing: post-earnings, guidance update reported Aug 14

Background

GrowGeneration is a specialty retailer/distributor focused on cultivation and gardening products, reporting Q2 2026 results and updating 2026 guidance.

Company-level read

Ticker impact

$GRWGBullishMedium confidence
Context

GrowGeneration reported Q2 2026 results and raised full-year adjusted EBITDA outlook to $2-$3 million from breakeven.

Expected impact

Likely positive near-term bias as traders price in improved operating leverage and sequential growth into Q3.

Evidence & confidence

The article provides multiple concrete datapoints: narrower EPS loss, positive adjusted EBITDA, higher gross margin, and an explicit full-year adjusted EBITDA raise.

Market effects

Improving profitability at a specialty ag retailer may modestly support sentiment for adjacent agricultural retail and input distribution names.

No specific regional spillover described beyond US-listed small-cap earnings/guidance read-through.

Limited global relevance; only a brief mention of tariff-related benefits without broader cross-border details.

Counterpoint

Despite the EBITDA raise, cash declined and inventory remains elevated, which could pressure future working-capital needs.

Key entities

  • GrowGeneration Corp.

    Reported Q2 2026 loss of $0.03 per share (narrower than consensus) and raised 2026 adjusted EBITDA outlook to $2-$3 million.

Related articles

$GRWGMedAI 8/10

GrowGeneration Corp. Q2 2026 Earnings Call Summary

GrowGeneration Corp. reported a third straight quarter of YoY revenue growth, citing a shift to a commercial B2B platform and proprietary brands. Proprietary brand penetration reached 40% ahead of schedule. The company cut store and operating expenses 22% YoY and raised full-year 2026 adjusted EBITDA guidance to $2M-$3M, aided by expected Q3 IEPA tariff refunds. It repurchased 700,000 shares at $1.38.

$GRWGMedAI 8/10

GrowGeneration (GRWG) Q2 2026 Earnings Call Transcript

GrowGeneration (GRWG) reported Q2 2026 revenue of $43.2 million, up 5.5% year over year, with adjusted EBITDA of $0.3 million versus a $1.3 million loss a year earlier. Net loss narrowed to $2.0 million. Gross margin rose to 28.5%. Full-year 2026 guidance: revenue $162-$168 million and adjusted EBITDA $2-$3 million. Cash was $41 million with no debt.

$MRCYMed

Mercury Systems 3Q 2026: Revenue $253.15M, EPS $0.21 — 10-Q Summary

Mercury Systems reported 3Q 2026 revenue of $253.15M, up 12.4% YoY, and net income of $13.09M, reversing a prior-year loss. Growth in radar and electronic warfare applications drove results, while C4I revenue declined. Gross margin improved to 35.2% from 27.9%. The company expects to recognize 46% of its $1.193B remaining performance obligations as revenue in the next 12 months.

$SNWVMed

Sanuwave Announces Q3 FY2026 Financial Results

SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanuwave Announces Q3 FY2026 Financial Results Q3 2026 revenues were $8.6 million, down 24% from $11.3 million in Q3 2025. Q3 2026 gross margin was 77.3%, versus 77.6% in Q3 2025. GAAP operating loss was $1.1 million for Q3 2026 versus operating income of $0.9 millio

$CPIXHighAI 8/10

CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE

CUMBERLAND PHARMACEUTICALS INC (CPIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE $100 million Strategic Transaction Closed Plans to Submit New Drug Application for Ifetroban in DMD Top-Line Results Announced for Systemic Sclerosis Trial NASHVILLE, Tenn. (Nov. 10, 2026) – Cumberland

$ATROHighAI 8/10

Astronics shares tumble on soft fourth quarter revenue outlook

Astronics (ATRO) reported Q3 earnings of $1.08 per share, beating estimates, with revenue up 28.5% YoY to $271.7M. However, shares fell 11% on Q4 revenue guidance of $255M-$275M, below expectations. The company maintained its full-year 2026 revenue guidance. Aerospace segment sales hit a record $245.5M, with strong demand in inflight entertainment and connectivity.